Condition

Emesis

ClinicalTrials.gov condition label

Clinical trials3

Recruiting0

Common interventions6

Lead sponsors shown3

Clinical trials

3 shown

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based ChemotherapyNCT02407600 · 2015-04-01

Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.NCT01913990 · 2011-09-01

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer PatientsNCT00869973 · 2009-09-01

Common interventions

AprepitantDRUG1 Arm A: Standard Anti-emetic regimenOTHER1 dexamethasoneDRUG1 Dexamethasone, Ondansetron, AprepitantDRUG1 FOSAPREPITANT (Emend)DRUG1 PlaceboDRUG1

Leading sponsors

Ajeet Gajra1 Ottawa Hospital Research Institute1 S. Maria Hospital, Terni1

Trial status mix

UNKNOWN2

TERMINATED1

Phase mix

PHASE21

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.